SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


Date of Report (Date of Earliest Event Reported):  JUNE 16, 2000
                                                   --------------

                          TRANSKARYOTIC THERAPIES, INC.
         -----------------------------------------------------------------
             (Exact Name of Registrant as Specified in its Charter)

                                    DELAWARE
         -----------------------------------------------------------------
                 (State or Other Jurisdiction of Incorporation)

                                  
                      000-21481                          04-3027191
         (Commission File Number)             (IRS Employer Identification No.)

         195 ALBANY STREET, CAMBRIDGE, MASSACHUSETTS             02139
         ----------------------------------------------------------------------
         (Address of Principal Executive Offices)              (Zip Code)

         

                                 (617) 349-0200
         -----------------------------------------------------------------
               Registrant's Telephone Number, Including Area Code

                                 NOT APPLICABLE
         -----------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)



Item 5. OTHER EVENTS.

         On June 16, 2000, Transkaryotic Therapies, Inc. (the "Registrant")
sold 1,000 shares of the Registrant's Series A Convertible Preferred Stock,
$0.01 par value per share, for an aggregate price of $10,000,000 to
investment funds affiliated with E.M. Warburg, Pincus & Co., L.L.C.
(collectively, "Warburg Pincus") pursuant to a Stock Purchase Agreement,
dated as of May 18, 2000 (the "Purchase Agreement"). Under the terms of the
Purchase Agreement, the 1,000 shares of Series A Convertible Preferred Stock
shall convert into approximately 357,000 shares of the Registrant's common
stock, $0.01 par value per share, at a conversion price of $28.00 per share.

                                      -2-



                                    SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date: June 16, 2000

                            TRANSKARYOTIC THERAPIES, INC.
                                  (Registrant)

                            By: /s/ Daniel E. Geffken
                               ------------------------------------------------
                            Daniel E. Geffken
                            Vice President, Finance and Chief Financial Officer